Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4128291 | Annales de Pathologie | 2014 | 8 Pages |
Abstract
Peritoneal malignant mesothelioma is a rare tumor, less common than its pleural counterpart. It develops from the mesothelial cells overlying peritoneum and preferentially occurs in male, with an average age ranging from 47Â to 60.5Â years. Asbestos whose impact is less strong than in pleural mesothelioma, SV 40Â virus, chronic peritonitis could be implicated as factors favoring the development of peritoneal mesothelioma. Clinical symptoms are not specific, and the imagery remains little or not contributive. The 2004Â WHO classification recognizes 3Â different types, which differ in terms of presentation and prognosis: diffuse epithelioid mesothelioma (the most common), sarcomatoid mesothelioma and biphasic mesothelioma. Many variants are described within these groups. Immunohistochemistry is mandatory to affirm or disprove peritoneal malignant mesothelioma diagnosis, based on a panel of antibodies divided in positive markers and negative markers. Indeed an accurate diagnosis is necessary to define a therapeutic strategy more and more frequently based on the combination of radical surgery and hyperthermic intra peritoneal chemotherapy. Such an approach significantly improves the prognosis of these aggressive diseases.
Related Topics
Health Sciences
Medicine and Dentistry
Pathology and Medical Technology
Authors
Ãliane Mery, Juliette Hommell-Fontaine, Mathieu Capovilla, Anne Chevallier, Frédéric Bibeau, Sabrina Croce, Peggy Dartigues, Rachid Kaci, Gerlinde Lang-Averous, Marie-Hélène Laverriere, Agnès Leroux-Broussier, Flora Poizat, Nina Robin,